TREMFYA for Psoriasis

This trial examines the presence of the medication guselkumab (marketed as TREMFYA) in breast milk. Guselkumab treats conditions such as psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease. The study collects breast milk samples from women already receiving guselkumab treatment. Ideal candidates are at least five weeks postpartum, exclusively breastfeeding, and have completed at least two doses of guselkumab. As a Phase 4 trial, this research aims to understand how this FDA-approved and effective treatment benefits more patients.

Previous studies have shown that guselkumab is well-tolerated by patients with conditions like psoriasis and psoriatic arthritis. Research indicates that its safety remains consistent across these conditions, without causing unexpected side effects. The most common side effects, affecting more than 1% of people, are mild, such as upper respiratory infections. These findings are based on data collected over five years from adults with moderate to severe psoriasis. The long-term data suggest that guselkumab is safe to use, offering reassurance to those considering participation in a clinical trial involving this treatment.¹²³⁴⁵

Guselkumab is unique because it targets the p19 subunit of interleukin-23 (IL-23), a key player in the inflammation process of psoriasis. Unlike traditional treatments like methotrexate or TNF inhibitors, guselkumab specifically blocks IL-23, which may lead to fewer side effects and a more tailored approach to reducing inflammation. Researchers are excited about this treatment because it offers a different mechanism of action that can potentially provide better and more sustained relief for patients with psoriasis. Plus, its dosing regimen, with options for administration every 4 or 8 weeks, adds flexibility and convenience for patients.

Research has shown that guselkumab effectively treats psoriasis. In one study, 64% of patients experienced significant skin improvement by Week 16. Another study found that nearly 90% of participants maintained clearer skin after 48 weeks. Long-term evidence supports its effectiveness, with almost 65% of patients achieving completely clear skin after four years. Additionally, a review of several studies confirmed that guselkumab significantly improves moderate-to-severe psoriasis without a large increase in side effects. These findings suggest that guselkumab is a reliable option for managing psoriasis. Participants in this trial will receive guselkumab maintenance therapy, with some receiving it once every 4 weeks and others once every 8 weeks, to further evaluate its effects.²⁶⁷⁸⁹